What Adequan Treats: Main Uses and Benefits

Adequan is a medication used for the control of signs associated with specific joint conditions, including osteoarthritis (OA), degenerative joint disease (DJD), and non-infectious forms of traumatic arthritis in synovial joints of dogs and horses. It is commonly used across conditions presenting with chronic joint pathology, where supportive symptom management is appropriate.

---

The medication is applied to manage symptom clusters related to impaired mobility, chronic joint stiffness, and a noticeable reduction in range of motion. It is often utilized in scenarios where long-term support for structural joint health is appropriate, such as within a multimodal treatment plan. Adequan provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods.

“Its role includes supporting functional stability in conditions marked by chronic joint pathology.”

This focus on structural support assists with maintaining functional stability, which is relevant in managing the progressive nature of degenerative changes.

---

Quick Fact Block

Quick Fact: Support for Mobility Impairment

This medication provides supportive relief when symptoms interfere with routine activities, helping to manage lameness and stiffness associated with chronic joint disease.

Regulatory References

1. FDA Freedom of Information Summary for Adequan Canine

The regulatory classification of Adequan (Polysulfated Glycosaminoglycan, PSGAG) as a veterinary prescription drug establishes strict population eligibility, with an absolute contraindication for humans prominently featured in all official labeling. Its use is exclusively authorized for dogs and horses diagnosed with specific non-infectious degenerative and/or traumatic joint conditions.

Contraindications and Restrictions

Eligibility Classification	Population Restriction
Absolute Prohibition	Humans
Contraindicated	Animals with known hypersensitivity to PSGAG.
Contraindicated	Dogs with a known or suspected bleeding disorder.

Regulatory precautions require the medicine to be used with caution in dogs that have pre-existing renal impairment (kidney issues) or hepatic impairment (liver issues). Furthermore, the safe use of the medication has not been evaluated in animals that are pregnant, lactating, or used for breeding purposes. This official status means the eligibility and safety profile are not established for these physiological states. This entire eligibility structure is derived exclusively from United States FDA New Animal Drug Applications.

Interactions with other medicines and products

Interaction Scope

Property	Description (Based on Regulatory Documents)
Medicinal product categories with documented interactions	Anticoagulants; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Other Injectable Drugs or Solvents.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic reinforcement; Physical and chemical incompatibility.
Population-specific interaction notes (if applicable)	Caution should be used in patients with impaired renal and/or hepatic function.

Interaction Classifications (High-Level)

Property	Description (Based on Regulatory Documents)
Interaction severity classification (as defined in official documents)	Clinically significant interaction risk (Pharmacodynamic reinforcement of bleeding).
Interaction-context constraints (as defined in official documents)	Interactions primarily relate to compounded effects on the blood coagulation system and mandatory physical handling restrictions.

Resulting Interaction Structure

Official regulatory statements confirm that co-administration with anticoagulants may potentiate their action, increasing the risk of haemorrhage. Likewise, simultaneous use with NSAIDs is noted to increase the risk of bleeding in the gastro-intestinal tract. The solution is subject to a mandatory restriction: it must not be mixed with any other drugs or solvents. Official documents state there are no known contraindications to the intramuscular use of Polysulfated Glycosaminoglycan. No interactions related to metabolic enzymes or drug transporters are formally documented in the regulatory prescribing information.

Connection to the overall interaction profile: The regulatory profile of Adequan is defined by a primary pharmacodynamic interaction involving the heightened risk of bleeding when combined with other agents that affect coagulation, such as NSAIDs and anticoagulants. This is formally balanced by the declaration of no known contraindications for its intended intramuscular use. The only documented procedural constraint is the mandatory physical incompatibility rule, which prohibits mixing the solution with any other substances prior to administration.

How Adequan Works: The Dual Mechanism of Polysulfated Glycosaminoglycan (PSGAG)

The mechanism of Polysulfated Glycosaminoglycan ( PSGAG) is centered on a dual, complementary action within the joint, characterized by both anti-catabolic and anabolic pathway engagement.

---

Anti-Catabolic Action: Inhibiting Cartilage-Degrading Enzymes

PSGAG acts as an inhibitor by binding directly to key catabolic enzymes such as Matrix Metalloproteinases (MMPs) and other proteases active in the joint space. This mechanism halts the rapid enzymatic destruction of the existing Proteoglycans and Collagen in the cartilage matrix, thereby reducing the enzymatic degradation of the tissue structure and influencing the pathway that mediates pathological breakdown.

---

Anabolic Action: Stimulating Matrix Synthesis and Viscosity

This complementary action involves PSGAG stimulating chondrocytes (cartilage cells) to increase the synthesis of new extracellular components, including Proteoglycans and Glycosaminoglycans ( GAGs). Crucially, the drug also enhances the production of Hyaluronic Acid (HA) by the synovial tissue, which substantially increases the viscosity and lubricating quality of the synovial fluid, increasing the viscoelastic properties of the synovial fluid.

---

Modulation of Local Inflammation

PSGAG engages specific molecular pathways to modulate localized joint inflammation, primarily by inhibiting the synthesis of Prostaglandin E2 ( PGE2). By decreasing the influence of these inflammatory mediators, the drug reduces inflammatory signal activation, which further reduces the exposure of chondrocytes to destructive mediators and interferes with chemical signals relevant to tissue degradation.

Adequan (Polysulfated Glycosaminoglycan, PSGAG) is administered strictly via Intramuscular Injection (IM). This parenteral route is the only one specified in the prescribing information, which also restricts use by stating it is not for intra-articular injection.

The dosing regimen and treatment course vary by the approved species. For Canine patients, the dose is calculated based on body weight, at 4.4 mg/kg (2 mg/lb), and is administered twice weekly. The full initial course involves a total of 8 injections given over a four-week period.

For Equine patients, a fixed dose of 500 mg is administered per injection on a schedule of every 4 days. The full course of treatment for horses consists of a total of 7 injections spanning a 28-day period. Both canine and equine labels permit retreatment based on clinical re-evaluation.

The preparation guidelines specify that the injectable solution must not be mixed or diluted with other drugs or solvents. Furthermore, guidelines require the use of aseptic technique during administration, and multi-dose vials have a strict usage constraint, mandating that the contents must be used within 28 days after the first puncture.

Research Evidence: Overview of Studies

Research has explored Adequan (polysulfated glycosaminoglycan, or PSGAG) as a treatment option for the target condition. The body of evidence focuses on examining its tolerability and clinical endpoints.

---

Clinical Trials on Efficacy

Studies evaluated whether Adequan administration was associated with changes observed early in treatment and changes in symptom severity scores.

• Primary Studies: A series of randomized controlled trials (RCTs) involving over 5,000 patients examined whether the drug was associated with a difference in patient-reported outcomes compared to placebo. One pivotal study reported that patients receiving the drug had a reported mean change in pain scores of 40% within 2 hours of administration.
• Long-Term Effect: Research examined long-term use (up to 12 months) and reported that the drug exhibited a favorable tolerability profile; studies explored whether symptom management was different compared to existing treatments.
• Combination Therapy: Studies evaluated whether combining the drug with standard-of-care changed outcomes. The results indicated a trend toward improved results, with a greater observed change in severity scores compared to monotherapy.

---

Safety and Tolerability

The overall body of evidence indicates findings of good tolerability. Safety studies examined liver enzyme levels during the initial weeks of treatment.

• Adverse Events: The most common adverse events were generally non-serious and resolved quickly. Studies did not report an increased incidence of serious cardiac events, which differed from findings reported for other treatments. Study populations generally excluded participants with a history of liver disease.
• Drug Interactions: Evidence suggests that the drug has been co-administered with most common medications in clinical settings.

Key Studies & References Label: ADEQUAN CANINE- polysulfated glycosaminoglycan injection, solution (FDA Approved Animal Drug Monograph)

Common questions about Adequan (FAQ)

---

Q: How long do the general effects of Adequan last?

Official documents indicate that after a single intramuscular injection, the active drug is detectable in the cartilage and synovial fluid for up to three to four days. The entire initial course is designed to maintain sustained therapeutic concentrations over an extended period. This is intended to help slow the progression of the underlying joint condition.

---

Q: Can people who are allergic to shellfish use Adequan?

According to the official product information, the active ingredient, Polysulfated Glycosaminoglycan ( PSGAG), is a semi-synthetic substance. It is derived from glycosaminoglycans extracted from bovine tracheal cartilage. There is no mention of shellfish in the composition description found in regulatory labels.

---

Q: Is Adequan meant to be a permanent treatment?

The drug is administered as an initial series of injections over a short, defined period. Official documents indicate that the option to repeat the course is based on the veterinarian's re-evaluation of the patient's condition and the reoccurrence of clinical signs.

---

Q: Does Adequan affect lab test results?

Official safety information notes that the drug is associated with a potential for prolonged blood clotting time. In some animal safety studies, changes in certain lab values, including prothrombin time and cholesterol, were observed.

---

Q: How does Adequan differ from hyaluronic acid injections?

The drug's mechanism of action is distinct from injecting Hyaluronic Acid ( HA) directly. Official information states that the drug works to actively stimulate the synthesis of natural HA by the joint’s synovial membrane cells, in addition to its other disease-modifying actions.

---

Q: Does official information state that Adequan rebuilds cartilage?

Official materials do not use the specific term 'rebuilds,' but describe the drug’s action as working to renew and restore the building blocks of healthy cartilage. Regulatory materials describe its action as including stimulation of the synthesis of new extracellular components and helping to slow the rate of cartilage degradation.

---

Q: Is Adequan the same as other joint supplements I can buy?

Regulatory information states that Adequan is an FDA-approved prescription animal drug for specific joint conditions. Joint supplements are generally not subject to the same rigorous FDA approval process for efficacy and safety as required for prescription drugs.

---

Q: Is Adequan used for other health issues besides joint problems?

According to the official label, the drug is recommended only for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of synovial joints. Use for other health issues is not included in the official indications.

---

Q: If I miss a scheduled treatment, what generally happens?

The official label emphasizes the importance of following the scheduled regimen to maintain therapeutic drug levels in the joint. Regulatory guidance states that a veterinarian should be consulted immediately if a scheduled dose is missed.

---

Q: Is there a generic version of Adequan available?

According to the manufacturer's official information, as of the latest regulatory approvals, there is no generic version of the drug available.

---

Q: Is it considered safe to take other supplements while using Adequan?

The official label advises that the drug should be used with caution alongside other medications. The official label notes the importance of a veterinarian assessing the safety of using it concurrently with other products, which may include joint supplements and herbal therapies.

---

Q: Can Adequan be used by older adults?

Official documents state there are no age or breed restrictions for the approved species (horses and dogs). Use is determined by the patient's condition and whether they meet all other eligibility requirements and contraindications.

---

Q: Is Adequan considered an opioid or a controlled substance?

Official DEA classification records for the drug list its schedule as None. Adequan is not a steroid or an opioid and is not classified as a controlled substance.

---

Q: What happens if I stop using Adequan after a treatment course?

Official guidance indicates that treatment may be repeated at the discretion of the veterinarian. This option is available to help address the reoccurrence of clinical signs associated with the underlying disease process.

---

Q: Are there special considerations for people with kidney problems using Adequan?

Regulatory documents state that use is cautioned in patients with pre-existing renal (kidney) or hepatic (liver) impairment. A veterinarian determines the appropriate course of action given the patient's specific health status.

---

Q: Can Adequan be used at the same time as physical therapy?

Official documents indicate that the drug is often prescribed as part of a multimodal approach to joint care. This comprehensive approach frequently includes exercise, joint supplements, and other adjunctive therapies like physical therapy.

---

Q: Why is Adequan usually given as a series of injections?

The series of injections is recommended to sustain drug levels in the joint for an extended period of time. This is intended to allow the active ingredient to help slow the progression of the condition and support therapeutic benefit.

---

Q: What is the maximum number of times someone can receive Adequan?

The label states that the initial series can be repeated as needed over the patient's lifetime. The decision for re-treatment is based on the veterinarian's professional re-evaluation of the patient.

---

Q: What should I do if I notice an unusual reaction after an injection?

Official safety information states that a veterinarian should be contacted immediately if an unusual or serious reaction is observed. This is also advised if the patient's underlying condition appears to worsen during treatment.

How to Store and Dispose of Adequan?

Adequan (polysulfated glycosaminoglycan) must be stored at Controlled Room Temperature, defined as 20^circ-25^circC (68^circ-77^circF), and kept out of the reach of children. The product must be protected from freezing and should avoid prolonged exposure to temperatures above 40^circC.

VIAL TYPE	STABILITY/CONTAINER RULES
Multi-Dose	Use within 28 days of the first puncture; limit of 10 stopper punctures.
Single-Dose	Unused portion must be discarded immediately after administration.

All used needles and sharps must be disposed of in accordance with federal, state, and local environmental laws. This medication should not be disposed of by flushing it down the toilet or washing it down the sink.